PPI · B12 deficiency · screening

PPI and B12 Deficiency: Screening Long-Term Acid Suppression

Check B12 in patients past two years of continuous PPI use or on high dose, adding magnesium and iron where the history warrants: two or more years of supply raised the odds of B12 deficiency to 1.65, and to 1.95 above 1.5 pills daily.

Acid suppression outlives its indication in a large share of patients. The absorption cost is dose-graded, the rebound is predictable, and both belong on the record before the next medication review.

PPI and B12 deficiency is a dose-graded association that most medication reviews never check, in a drug class that routinely outlives its indication. Estimates of inappropriate proton pump inhibitor prescribing run between 25% and 70%. The clinical argument is laid out in The Heartburn Pill You Can’t Quit, the chapter video for The Angry Gut (Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes). For the treating physician the operational questions are narrower: which long-term users to screen, what a finding changes in management, and how to document it so the review happens again next year.

Retire the hypochlorhydria model of reflux first

I taught the low-acid explanation of reflux for years, and it does not survive human testing. Under a week of twice-daily omeprazole, impedance-measured reflux episodes did not decline; acid reflux fell from 45% to 3% while non-acid reflux rose from 55% to 97%. In a separate series of 100 patients with manometry and pH studies, gastrin correlated with neither the DeMeester score nor sphincter pressure.

The drivers are mechanical. Transient sphincter relaxation rate tracks intragastric pressure at r = 0.91. Across 84 subjects in three weight categories, relaxation rates were 2.1, 3.8 and 7.3 an hour and the gastroesophageal pressure gradient climbed from 4.5 to 10.0 mm Hg, while resting sphincter pressure and length stayed comparable. After a meal, the acid pocket sat at or above the diaphragm during 22% of relaxations in healthy volunteers, 54% with a small hiatal hernia and 77% with a large one. Counsel on pressure and hernia anatomy, not on acid.

The age assumption fails as well. In 248 volunteers aged 65 and over, weighted prevalence of consistent hyposecretion was 11%, and across 41 healthy adults age independently raised acid output while H. pylori lowered it. Atrophic gastritis carries a global prevalence of 25.4% with no difference between symptomatic and asymptomatic individuals, so genuine hypochlorhydria is found by H. pylori testing and pepsinogens rather than by history. Gastric pH, impedance and acid output studies are not part of Measura [Cardiometabolic and Autonomic Health Analysis]; the autoimmune side is covered in intrinsic factor antibody screening.

Can a PPI such as omeprazole cause B12 deficiency?

Acid releases cobalamin from dietary protein, and the deficiency signal behaves like a dose response. The odds of B12 deficiency rose to 1.65 (95% CI, 1.58-1.73) with two or more years of PPI supply, compared with 1.25 for H2 receptor antagonists, rising to 1.95 above 1.5 pills daily. Mineral data are thinner and population-bound: hypomagnesemia at 2.16 (95% CI 1.46-3.20) in kidney transplant recipients, and iron deficiency at 1.57, or 2.30 on high dose, in renal transplant recipients. Protein handling shifts too, because pepsin requires an acid environment, which matters for the first brain as a whole and not only for one vitamin.

Keep the rest proportionate. The randomized safety trial of 17,598 participants over three years separated on enteric infection alone, 1.4% versus 1.0% (odds ratio 1.33), with dementia, fractures, pneumonia, chronic kidney disease and diabetes prespecified and null. Pooled randomized data put C. difficile at RR 1.19 across 29,880 participants, and fracture evidence is graded very low to low certainty. The screening case rests on absorption, not on headline harms.

What happens when a long-term PPI is stopped?

Withdrawal symptoms are pharmacology. In 120 healthy volunteers given eight weeks of a PPI or placebo, 44% (26/59) reported a clinically relevant acid-related symptom within four weeks of withdrawal versus 15% (9/59); a second trial found 11 of 25 versus 2 of 23. Onset clusters at day 5 to 14 with a mean duration of 4 to 5 days, 38% start later at week 3 or 4, and measured hypersecretion lasts more than 8 and under 26 weeks. Rebound tracks depth of suppression, not brand, and patients who are warned about it misread it less often as relapse.

Set expectations from the trials. A year after a structured discontinuation attempt, 27% of long-term users were off the drug; tapering and abrupt stopping did not differ (31% versus 22%), patients with reflux disease succeeded less often (21% versus 48%), and baseline gastrin predicted resumption. Expert guidance offers a discontinuation trial to patients without a definite indication and steps twice-daily dosing to once daily first. Barrett’s esophagus, severe erosive esophagitis, esophageal ulcer, stricture, eosinophilic esophagitis and idiopathic pulmonary fibrosis stay on therapy. Alginate gives patients a non-suppressant option through the rebound window. Whether and how to discontinue remains the prescriber’s decision, made with the patient on the basis of indication.

What to measure, and what each result changes

• Laboratory panels. B12 in patients past two years of continuous suppression or on high dose, with magnesium and iron where the history warrants. A low value is a management finding in its own right and a prompt to revisit the indication.
• Bioimpedance body composition. Weight loss and head-of-bed elevation were the only lifestyle measures supported on systematic review, so a documented abdominal fat burden gives the reflux plan a mechanical target and a follow-up metric. Visceral adiposity is also the metaflammation substrate that a subsidized acellular-carbohydrate food supply keeps rebuilding.
• Vestibular and balance testing. In older users where fracture concern enters the conversation, fall risk measured directly is actionable in a way a low-certainty drug association is not.
• Cognitive assessment. The observational dementia hazard ratio of 1.44 did not reproduce under randomization. A memory complaint in a long-term user deserves its own measurement rather than attribution to the drug.

Measura reports to the ordering physician. It does not diagnose reflux, measure gastric acid or manage medication.

Documentation and standing orders

Suppression outlives indication because renewal is frictionless and review is not. A standing order can attach a B12-inclusive panel to documented PPI use of two years or more and require an indication field at each renewal. The medication review fits the annual wellness visit, and fall-risk findings pair with the approach in cognitive assessment and fall prevention. Results flow into the chart as described in getting results into the record. Supporting evidence, study by study, is in the companion deep dive for The Angry Gut; the patient explanation is long-term PPI use for patients, and opioid-induced constipation screening follows the next drug class that stalls the gut.

Frequently asked questions

Which patients on PPIs should be screened for B12 deficiency?

Prioritize patients with two or more years of continuous supply and those taking more than 1.5 pills a day, where the odds ratio reached 1.95. Add older adults and anyone whose original indication is no longer documented. The last group also needs an indication review. Review the selection criteria.

Does hypochlorhydria cause reflux in older patients?

No. Profound drug-induced hypochlorhydria left reflux episode counts unchanged, and in 248 adults aged 65 and over only 11% consistently hyposecreted. Reflux follows intragastric pressure, the pressure gradient and acid pocket position relative to a hiatal hernia. Suspected true hypochlorhydria calls for H. pylori testing and pepsinogens, not empiric acid replacement. Read the clinical rationale.

How long does rebound acid hypersecretion last after PPI withdrawal?

Typical onset falls between day 5 and 14, with symptoms averaging 4 to 5 days, though 38% begin at week 3 or 4. Measured hypersecretion persists more than 8 weeks and under 26. Symptoms still present at week six suggest persistent reflux disease rather than rebound, which changes the conversation about continuing therapy. See more physician questions.

Are dementia and fracture risk reasons to screen long-term PPI users?

Not on current evidence. A three-year randomized trial of 17,598 participants found no difference in dementia or fractures, and fracture evidence overall is very low to low certainty. Screen for what the data support, absorption, and measure cognition or fall risk when the patient presents a reason to, not because of the prescription. See guidance on interpreting the report.

Does Measura measure gastric acid or reflux?

No. Gastric pH, impedance, acid output studies, endoscopy and H. pylori testing are gastroenterology services performed elsewhere. Measura provides laboratory panels, body composition, balance, cognitive, autonomic and vascular measurement, reported to the ordering physician, who integrates the results with the gastrointestinal workup and makes any medication decision. Read about onboarding the protocol.

How common is B12 deficiency with PPI use?

The data describe relative risk that climbs with exposure rather than a single rate. Two or more years of PPI supply raised the odds of B12 deficiency to 1.65, against 1.25 for H2 receptor antagonists, and to 1.95 above 1.5 pills daily. With inappropriate PPI prescribing estimated at 25% to 70%, the exposed population in any practice panel is larger than the indications alone would suggest.

Can acid reflux cause B12 deficiency?

The deficiency signal attaches to acid suppression, not to reflux. Acid releases cobalamin from dietary protein, and the odds rise with years and dose of PPI therapy. Reflux itself is a pressure disorder. Where low B12 appears without long-term suppression, genuine hypochlorhydria from atrophic gastritis or H. pylori is identified with H. pylori testing and pepsinogens, and the autoimmune side with intrinsic factor antibody screening.

References

• Vela, M. F., Camacho-Lobato, L., Srinivasan, R., Tutuian, R., Katz, P. O., & Castell, D. O. (2001). Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology, 120(7), 1599-606. https://doi.org/10.1053/gast.2001.24840
• Wu, J. C. Y., Mui, L. M., Cheung, C. M. Y., Chan, Y., & Sung, J. J. Y. (2006). Obesity is associated with increased transient lower esophageal sphincter relaxation. Gastroenterology, 132(3), 883-9. https://doi.org/10.1053/j.gastro.2006.12.032
• Hurwitz, A., Brady, D. A., Schaal, S. E., Samloff, I. M., Dedon, J., & Ruhl, C. E. (1997). Gastric acidity in older adults. JAMA, 278(8), 659-62. https://pubmed.ncbi.nlm.nih.gov/9272898/
• Mulder, D. T., Hahn, A. I., Huang, R. J., Zhou, M. J., Blake, B., Omofuma, O., Murphy, J. D., Gutierrez-Torres, D. S., Zauber, A. G., O’Mahony, J. F., Camargo, M. C., Ladabaum, U., Yeh, J. M., Hur, C., Lansdorp-Vogelaar, I., Meester, R., & Laszkowska, M. (2024). Prevalence of Gastric Precursor Lesions in Countries With Differential Gastric Cancer Burden: A Systematic Review and Meta-analysis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 22(8), 1605-1617.e46. https://doi.org/10.1016/j.cgh.2024.02.023
• Lam, J. R., Schneider, J. L., Zhao, W., & Corley, D. A. (2013). Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA, 310(22), 2435-42. https://doi.org/10.1001/jama.2013.280490
• Mohammadi, K., Yaribash, S., Razi, B., & Dashti-Khavidaki, S. (2021). Comparing safety of proton-pump inhibitors versus H2-receptor antagonists in kidney transplant recipients: A systematic review and meta-analysis. Journal of clinical pharmacy and therapeutics, 47(5), 567-574. https://doi.org/10.1111/jcpt.13589
• Moayyedi, P., Eikelboom, J. W., Bosch, J., Connolly, S. J., Dyal, L., Shestakovska, O., Leong, D., Anand, S. S., Stork, S., Branch, K. R. H., Bhatt, D. L., Verhamme, P. B., O’Donnell, M., Maggioni, A. P., Lonn, E. M., Piegas, L. S., Ertl, G., Keltai, M., Bruns, N. C., … Yusuf, S. (2019). Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Gastroenterology, 157(3), 682-691.e2. https://doi.org/10.1053/j.gastro.2019.05.056
• Reimer, C., Søndergaard, B., Hilsted, L., & Bytzer, P. (2009). Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology, 137(1), 80-87, 87.e1. https://doi.org/10.1053/j.gastro.2009.03.058
• Björnsson, E., Abrahamsson, H., Simrén, M., Mattsson, N., Jensen, C., Agerforz, P., & Kilander, A. (2006). Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Alimentary Pharmacology & Therapeutics, 24(6), 945-954. https://doi.org/10.1111/j.1365-2036.2006.03084.x
• Targownik, L. E., Fisher, D. A., & Saini, S. D. (2022). AGA Clinical Practice Update on de-prescribing of proton pump inhibitors: Expert review. Gastroenterology, 162(4), 1334-1342. https://doi.org/10.1053/j.gastro.2021.12.247

Related reading

• Intermittent Fasting in Type 2 Diabetes: Measure First
• Opioid-Induced Constipation: Screening in Long-Term Therapy
• Laboratory Panels

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, medical director of Measura. Last reviewed September 12, 2026.